These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 36071523)

  • 61. Novel insights into the interaction between N6-methyladenosine methylation and noncoding RNAs in musculoskeletal disorders.
    Han J; Kong H; Wang X; Zhang XA
    Cell Prolif; 2022 Oct; 55(10):e13294. PubMed ID: 35735243
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 63. m
    Huang H; Weng H; Chen J
    Cancer Cell; 2020 Mar; 37(3):270-288. PubMed ID: 32183948
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification and Validation of N6-Methyladenosine-Related Biomarkers for Bladder Cancer: Implications for Immunotherapy.
    Deng H; Tang F; Zhou M; Shan D; Chen X; Cao K
    Front Oncol; 2022; 12():820242. PubMed ID: 35311150
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cyclodextrin-Functionalized Gold Nanorods Loaded with Meclofenamic Acid for Improving
    Liu J; Song Y; Wang Y; Han M; Wang C; Yan F
    ACS Appl Mater Interfaces; 2022 Sep; 14(36):40612-40623. PubMed ID: 36053499
    [TBL] [Abstract][Full Text] [Related]  

  • 66. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comprehensive analysis of m
    Liu T; Li H; Du G; Ma J; Shen J; Zhao H; Luo F; Li H
    Gene; 2022 May; 821():146250. PubMed ID: 35151825
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Potential roles of N6-methyladenosine (m6A) in immune cells.
    Liu C; Yang Z; Li R; Wu Y; Chi M; Gao S; Sun X; Meng X; Wang B
    J Transl Med; 2021 Jun; 19(1):251. PubMed ID: 34103054
    [TBL] [Abstract][Full Text] [Related]  

  • 69.
    Mo P; Xie S; Cai W; Ruan J; Du Q; Ye J; Mao J
    J Int Med Res; 2020 Sep; 48(9):300060520951405. PubMed ID: 32972288
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Research advances of N6-methyladenosine in diagnosis and therapy of pancreatic cancer.
    Chen S; Ren H; Zhang X; Chang L; Wang Z; Wu H; Zhang J; Ren J; Zhou L
    J Clin Lab Anal; 2022 Sep; 36(9):e24611. PubMed ID: 35837987
    [TBL] [Abstract][Full Text] [Related]  

  • 71. N6-methyladenosine RNA modification in cancer therapeutic resistance: Current status and perspectives.
    Xu Z; Peng B; Cai Y; Wu G; Huang J; Gao M; Guo G; Zeng S; Gong Z; Yan Y
    Biochem Pharmacol; 2020 Dec; 182():114258. PubMed ID: 33017575
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy.
    Liu Z; Zhong J; Zeng J; Duan X; Lu J; Sun X; Liu Q; Liang Y; Lin Z; Zhong W; Wu W; Cai C; Zeng G
    Front Immunol; 2021; 12():735170. PubMed ID: 34531875
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immune infiltration-related N6-methyladenosine RNA methylation regulators influence the malignancy and prognosis of endometrial cancer.
    Ma J; Yang D; Ma XX
    Aging (Albany NY); 2021 Jun; 13(12):16287-16315. PubMed ID: 34230220
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
    Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
    BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis.
    Chen M; Wong CM
    Mol Cancer; 2020 Feb; 19(1):44. PubMed ID: 32111216
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The N
    Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
    Front Immunol; 2021; 12():653711. PubMed ID: 34354698
    [TBL] [Abstract][Full Text] [Related]  

  • 77. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
    Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y
    Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The role of m6A RNA methylation in cancer.
    Sun T; Wu R; Ming L
    Biomed Pharmacother; 2019 Apr; 112():108613. PubMed ID: 30784918
    [TBL] [Abstract][Full Text] [Related]  

  • 79. N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies.
    Tan F; Zhao M; Xiong F; Wang Y; Zhang S; Gong Z; Li X; He Y; Shi L; Wang F; Xiang B; Zhou M; Li X; Li Y; Li G; Zeng Z; Xiong W; Guo C
    J Exp Clin Cancer Res; 2021 Apr; 40(1):146. PubMed ID: 33926508
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Interaction between N
    Chen Y; Lin Y; Shu Y; He J; Gao W
    Mol Cancer; 2020 May; 19(1):94. PubMed ID: 32443966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.